CAJ | 학술논문

1999年由美国的Zhao和Drliea首先提出了防耐药突变浓度(MPC)和耐药突变选择窗(MSW)的假说.该假说认为每一种抗菌药物的浓度如果位于MSW内,那么细菌只需要一步突变而产生耐药,并且被选择性富集扩增,从而产生耐药.因此,这就为临床上抗菌药物的应用提供了一种新的给药策略,这种策略的关键在于将药物浓度提高到选择窗上界即MPC以上.近些年来,随着人们对该理论研究的深入,对该理论有了许多新的认识,为有效抑制细菌耐药及制定抗菌药物应用策略提供了新的思路和参考依据.
1999년유미국적Zhao화Drliea수선제출료방내약돌변농도(MPC)화내약돌변선택창(MSW)적가설.해가설인위매일충항균약물적농도여과위우MSW내,나요세균지수요일보돌변이산생내약,병차피선택성부집확증,종이산생내약.인차,저취위림상상항균약물적응용제공료일충신적급약책략,저충책략적관건재우장약물농도제고도선택창상계즉MPC이상.근사년래,수착인문대해이론연구적심입,대해이론유료허다신적인식,위유효억제세균내약급제정항균약물응용책략제공료신적사로화삼고의거.
In 1999, Zhao and Drlica put forward the hypothesis of mutant prevention concentration (MPC) and mutant selection window(MSW). They believe that for each antibacterial agents, if their concentration range exists in MSW, the drug-resistant mutants will arise and amplify which only need single-step mutant. So, this hypothesis provides a newdosing strategy for clinic. The key of this strategy is that raise the antibiot concentration to the upper boundary of selection window: MPC. In recent years,along with the study in this hypothesis deeply, some new viewpoints have been arised about those hypothesis, which provides the new method to restrain the resistant problem.